Other Clinical Trial - A Study to Assess the Effectiveness & Safety of

Status Completed

Clinical Trial Summary

This was a multicenter, non-interventional, retrospective study aiming to evaluate the real-world effectiveness and safety of siponimod treatment in Chinese patients with relapsing forms of multiple sclerosis (RMS). The data were collected retrospectively through medical records review and abstraction conducted at a single time point per patient by the investigator's site staff or a designate (at the discretion of the site, if allowed by local regulations). There was no prospective patient follow-up for this study. Obtaining informed consent was based on local regulations. Where permissible, waivers could be applied to the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) as appropriate, based on the retrospective collection of non-personally identifiable data, if acceptable per local regulations. The target patient population included adult patients diagnosed with RMS (including clinically isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), or active secondary progressive multiple sclerosis (SPMS)), and who received at least 3-months of treatment with siponimod after the index date. The index date is the date of siponimod initiation, defined as the date of first prescription record of siponimod in the patient's medical records with RMS diagnosis. Effectiveness data (i.e., clinical relapses, magnetic resonance imaging (MRI) activity) were collected from the index date, through the end of the observation period. The observation period was from the index date to the date of initiation of medical records abstraction at site, or patient withdrawal of consent, loss of follow-up, or death, whichever occurred first. Among patients who permanently discontinued siponimod during the observation period, safety data were collected up to 30 days after the last dose of siponimod.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinically Isolated Syndrome
Multiple Sclerosis
Multiple Sclerosis, Chronic Progressive
Multiple Sclerosis, Relapsing-Remitting
Relapsing Multiple Sclerosis
Relapsing Remitting Multiple Sclerosis
Sclerosis
Secondary Progressive Multiple Sclerosis

Clinical Trial Details

NCT number	NCT06395909
Study type	Observational
Source	Novartis
Contact
Status	Completed
Phase
Start date	April 23, 2023
Completion date	August 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01945359` - Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design	N/A
Completed	`NCT01456416` - Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities	Phase 4
Completed	`NCT01450124` - Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)	Phase 2
Recruiting	`NCT05277740` - Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis
Completed	`NCT03718247` - Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS
Active, not recruiting	`NCT03471338` - Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme	N/A
Recruiting	`NCT03004079` - Clinical Importance of Glucose Regulation in Relapsing MS
Terminated	`NCT02266121` - Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis	N/A
Completed	`NCT01963611` - Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)	Phase 2
Active, not recruiting	`NCT01464905` - Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)	Phase 3
Completed	`NCT01225289` - Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients	Phase 4
Recruiting	`NCT00242268` - A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis	Phase 3
Completed	`NCT00203086` - A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis	Phase 4
Completed	`NCT00616187` - Atorvastatin in Relapsing-Remitting Multiple Sclerosis	Phase 2
Recruiting	`NCT06083753` - Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis	Phase 2
Active, not recruiting	`NCT04602390` - Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis	Phase 1
Recruiting	`NCT06159712` - Comparative Study of High-Efficacy Disease Modifying Treatment of Relapsing Multiple Sclerosis	N/A
Recruiting	`NCT04604041` - Investigation of Subclinical Markers of Multiple Sclerosis
Terminated	`NCT03536559` - Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis	Phase 2
Completed	`NCT02490982` - Teriflunomide Observational Effectiveness Study

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms